Display options
Cite
Kevin RC, Kovach AL, Lefever TW, et al. Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. Forensic Toxicol. 2018;37(1):17-26doi: 10.1007/s11419-018-0430-0.
Kevin, R. C., Kovach, A. L., Lefever, T. W., Gamage, T. F., Wiley, J. L., McGregor, I. S., & Thomas, B. F. (2019). Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. Forensic toxicology, 37(1), 17-26. https://doi.org/10.1007/s11419-018-0430-0
Kevin, Richard C, et al. "Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures." Forensic toxicology vol. 37,1 (2019): 17-26. doi: https://doi.org/10.1007/s11419-018-0430-0
Kevin RC, Kovach AL, Lefever TW, Gamage TF, Wiley JL, McGregor IS, Thomas BF. Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. Forensic Toxicol. 2019 Jan;37(1):17-26. doi: 10.1007/s11419-018-0430-0. Epub 2018 Jun 28. PMID: 30705707; PMCID: PMC6349387.
Copy Download .nbib Format: NLM
Share it on

Forensic Toxicol. 2019 Jan;37(1):17-26. doi: 10.1007/s11419-018-0430-0. Epub 2018 Jun 28.

Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures.

Forensic toxicology

Richard C Kevin, Alexander L Kovach, Timothy W Lefever, Thomas F Gamage, Jenny L Wiley, Iain S McGregor, Brian F Thomas

Affiliations

  1. School of Psychology, The University of Sydney, NSW, 2006, Australia.
  2. RTI International, 3040 Cornwallis Road, Research Triangle Park, NC, 27709, USA.

PMID: 30705707 PMCID: PMC6349387 DOI: 10.1007/s11419-018-0430-0

Abstract

PURPOSE: The use of novel synthetic cannabinoids as intoxicants continues in spite of associated health risks. These compounds are typically smoked or vaporized, but many synthetic cannabinoids contain thermally labile chemical moieties. This study investigated the thermal stability six carboxamide-type synthetic cannabinoids (CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18) in order to characterise potential user exposure to thermolysis products.

METHODS: Compounds were heated sequentially to 200, 400, 600 and 800 °C using a thermolysis probe, and the resultant thermolysis products were analysed via GC-MS. A secondary analysis quantified thermolytically generated cyanide via LC-MS/MS.

RESULTS: All six synthetic cannabinoids underwent thermal degradation when heated above 400 °C, and released a variety of potentially toxic products, including toluene, naphthalene, and 1-naphthalamine. Compound-specific degradants were tentatively identified together with a general degradative pathway for carboxamide-type synthetic cannabinoids, which proceeds via indole- or indazole-amide formation and subsequent dehydration to an indole- or indazole-carbonitrile. This degradative pathway culminated in the thermolytic liberation of cyanide, in amounts up to 27 μg per mg of starting material.

CONCLUSIONS: People who smoke carboxamide-type synthetic cannabinoids are likely to be exposed to range of potentially toxic thermal degradants, including cyanide. These degradants could have significant health impacts in human users.

Keywords: Carboxamides; Cyanide; Degradants; Synthetic cannabinoids; Thermolytic products; Toxicity

Conflict of interest statement

Conflict of interest The authors have no conflict of interest to declare.

References

  1. Toxicology. 2002 Oct 30;180(1):97-105 - PubMed
  2. J Toxicol Environ Health B Crit Rev. 2003 Mar-Apr;6(2):161-83 - PubMed
  3. Bioorg Med Chem. 2005 Jan 3;13(1):89-112 - PubMed
  4. J Emerg Nurs. 2006 Aug;32(4 Suppl):S8-11 - PubMed
  5. Forensic Sci Int. 2010 Jul 15;200(1-3):141-7 - PubMed
  6. J AOAC Int. 2010 May-Jun;93(3):1032-8 - PubMed
  7. J Chromatogr A. 2011 Feb 18;1218(7):1016-9 - PubMed
  8. Pediatrics. 2011 Dec;128(6):e1622-7 - PubMed
  9. Addiction. 2013 Mar;108(3):534-44 - PubMed
  10. Clin J Am Soc Nephrol. 2013 Apr;8(4):523-6 - PubMed
  11. Forensic Sci Int. 2013 Mar 10;226(1-3):62-73 - PubMed
  12. Drug Test Anal. 2013 Aug;5(8):683-92 - PubMed
  13. J Anal Toxicol. 2013 Jun;37(5):265-76 - PubMed
  14. Neuropharmacology. 2013 Dec;75:145-54 - PubMed
  15. Forensic Sci Int. 2013 Dec 10;233(1-3):320-7 - PubMed
  16. Subst Abus. 2014;35(2):184-9 - PubMed
  17. Clin Toxicol (Phila). 2014 Aug;52(7):664-73 - PubMed
  18. J Emerg Med. 2015 May;48(5):573-80 - PubMed
  19. ACS Chem Neurosci. 2015 Sep 16;6(9):1546-59 - PubMed
  20. N Engl J Med. 2015 Jul 9;373(2):103-7 - PubMed
  21. ACS Chem Neurosci. 2016 Sep 21;7(9):1241-54 - PubMed
  22. N Am J Med Sci. 2016 Jun;8(6):256-8 - PubMed
  23. N Engl J Med. 2017 Jan 19;376(3):235-242 - PubMed
  24. Clin Toxicol (Phila). 2017 Mar;55(3):193-195 - PubMed
  25. J Pharmacol Exp Ther. 2017 Apr;361(1):162-171 - PubMed
  26. Subst Abuse. 2017 Apr 07;11:1178221817701739 - PubMed
  27. J Anal Toxicol. 2017 Jul 1;41(6):551-558 - PubMed
  28. J Pharmacol Exp Ther. 2018 May;365(2):437-446 - PubMed
  29. Drug Test Anal. 2018 Mar 25;:null - PubMed
  30. Clin Chem. 1987 Jul;33(7):1228-30 - PubMed
  31. Hum Toxicol. 1982 Jul;1(3):281-7 - PubMed

Publication Types

Grant support